Moderna (MRNA) Receivables - Net (2017 - 2026)

Moderna (MRNA) has reported Receivables - Net for 10 consecutive years, with $120.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables - Net fell 53.85% year-over-year to $120.0 million in Q2 2026; TTM through Jun 2026 was $120.0 million, a 53.85% decrease from a year earlier, with the FY2025 full-year figure at $368.0 million, down 47.28% from the prior year.
• Receivables - Net was $120.0 million for Q2 2026 at Moderna, down from $203.0 million in the prior quarter.
• Over five years, Receivables - Net peaked at $3.2 billion in Q1 2022 and troughed at $120.0 million in Q2 2026.
• A 5-year average of $1.3 billion and a median of $905.5 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net tumbled 91.38% in 2023 and jumped 112.07% in 2024, its largest moves.
• Over 5 years, Receivables - Net stood at $1.4 billion in 2022, then advanced by 14.37% to $1.6 billion in 2023, then slumped by 55.93% to $698.0 million in 2024, then tumbled by 47.28% to $368.0 million in 2025, then tumbled by 67.39% to $120.0 million in 2026.
• The last three Receivables - Net figures came in at $120.0 million (Q2 2026), $203.0 million (Q1 2026), and $368.0 million (Q4 2025), per Business Quant data.